نتایج جستجو برای: human papillomavirus 16 and 18 types

تعداد نتایج: 17180718  

Journal: :The Journal of infectious diseases 2010
Laia Bruni Mireia Diaz Xavier Castellsagué Elena Ferrer F Xavier Bosch Silvia de Sanjosé

BACKGROUND Baseline information on human papillomavirus (HPV) prevalence and type distribution is highly desirable to evaluate the impact of prophylactic HPV vaccines in the near future. METHODS A meta-analysis was performed of studies published between 1995 and 2009 that used polymerase chain reaction or Hybrid Capture 2 for HPV detection in women with normal cytological findings. RESULTS ...

Journal: :Clinical and vaccine immunology : CVI 2009
Mel Krajden Karuna Karunakaran Stacy So Joel M Palefsky Rachna Sharma Darrel Cook Amanda Yu Ron Chow Simon Dobson Gina S Ogilvie Martin Petric

Human papillomavirus (HPV) type 16 and 18 neutralizing antibody (NAb) titers were measured in 1,020 prenatal women in British Columbia aged 15 to 39. HPV 16 and 18 NAbs were detected in 183/1,020 (17.9%) and 97/1,020 (9.5%), respectively, and 39 (3.8%) had NAbs to both types. Titers were similar across age strata.

Journal: :Hong Kong medical journal = Xianggang yi xue za zhi 2010
Hextan Y S Ngan Annie N Y Cheung K F Tam Karen K L Chan H W Tang D Bi Dominique Descamps Hans L Bock

OBJECTIVE To assess the immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in Chinese women aged 18 to 35 years enrolled from Hong Kong. DESIGN Double-blind, randomised controlled trial with vaccine and placebo groups. SETTING Single-centre study in Hong Kong. PARTICIPANTS Three hundred women enrolled (150 per group) between March 2006 and June...

2016
Eva Herweijer Karin Sundström Alexander Ploner Ingrid Uhnoo Pär Sparén Lisen Arnheim‐Dahlström

Human papillomavirus (HPV) types 16/18, included in HPV vaccines, contribute to the majority of cervical cancer, and a substantial proportion of cervical intraepithelial neoplasia (CIN) grades 2/3 or worse (CIN2+/CIN3+) including adenocarcinoma in situ or worse. The aim of this study was to quantify the effect of quadrivalent HPV (qHPV) vaccination on incidence of CIN2+ and CIN3+. A nationwide ...

Journal: :Vaccine 2006
Luisa L Villa Kevin A Ault Anna R Giuliano Ronaldo L R Costa Carlos A Petta Rosires P Andrade Darron R Brown Alex Ferenczy Diane M Harper Laura A Koutsky Robert J Kurman Matti Lehtinen Christian Malm Sven-Eric Olsson Brigitte M Ronnett Finn Egil Skjeldestad Margareta Steinwall Mark H Stoler Cosette M Wheeler Frank J Taddeo Jimmy Yu Lisa Lupinacci Radha Railkar Rocio Marchese Mark T Esser Janine Bryan Kathrin U Jansen Heather L Sings Gretchen M Tamms Alfred J Saah Eliav Barr

Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All t...

Journal: :Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2004
Raphael P Viscidi Mark Schiffman Allan Hildesheim Rolando Herrero Philip E Castle Maria C Bratti Ana Cecilia Rodriguez Mark E Sherman Sophia Wang Barbara Clayman Robert D Burk

Whether antibodies to human papillomavirus (HPV) capsids, elicited by natural infection, are protective is unknown. This question was addressed in a population-based cohort of 7046 women in Costa Rica by examining the association between baseline seroreactivity to HPV-16, HPV-18, or HPV-31 virus-like particles and the risk of subsequent HPV infection at a follow-up visit 5-7 years after enrollm...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید